Highly effective production of biologically active, secreted, human granulocyte-macrophage colony-stimulating factor by recombinant vaccinia virus
- Authors: Grazhdantseva A.A.1,2, Sivolobova G.F.1,2, Tkacheva A.V.1,2, Gileva I.P.1, Kuligina E.V.2, Rikhter V.A.2, Kochneva G.V.1,2
-
Affiliations:
- State Research Center of Virology and Biotechnology “Vector”
- Institute of Chemical Biology and Fundamental Medicine
- Issue: Vol 52, No 7 (2016)
- Pages: 685-691
- Section: Producers, Biology, Selection, and Gene Engineering
- URL: https://journals.rcsi.science/0003-6838/article/view/152102
- DOI: https://doi.org/10.1134/S0003683816070036
- ID: 152102
Cite item
Abstract
The recombinant vaccinia virus strain VV-GMCSF-S1/3, which contains an insertion of full-length DNA copy of messenger RNA of human granulocyte-macrophage colony-stimulating factor (GM-CSF) in the structural part of the viral thymidine kinase gene, was obtained. The expression of the GM-CSF gene as a part of the recombinant virus is under the control of the native vaccinia virus promoter р7.5K; this results in the production of a mature form of the secreted protein with a molecular mass of 32 kDa. The biological activity of GM-CSF was evaluated by stimulation of the proliferation of cytokine-dependent human TF-1 erythroleukemia cells. The secretion level of biologically active human GM-CSF in the system of recombinant vaccinia virus/mammalian cells was 1–40 μg/mL of culture medium. The recombinant strain VV-GMCSF-S1/3 can be used as a producer of the glycosylated mature form of human GM-CSF, as well as a vector for the construction of oncolytic viruses and multivalent vaccine preparations.
About the authors
A. A. Grazhdantseva
State Research Center of Virology and Biotechnology “Vector”; Institute of Chemical Biology and Fundamental Medicine
Email: g.v.kochneva@yandex.ru
Russian Federation, Koltsovo, Novosibirsk Oblast, 630559; Novosibirsk, 630090
G. F. Sivolobova
State Research Center of Virology and Biotechnology “Vector”; Institute of Chemical Biology and Fundamental Medicine
Email: g.v.kochneva@yandex.ru
Russian Federation, Koltsovo, Novosibirsk Oblast, 630559; Novosibirsk, 630090
A. V. Tkacheva
State Research Center of Virology and Biotechnology “Vector”; Institute of Chemical Biology and Fundamental Medicine
Email: g.v.kochneva@yandex.ru
Russian Federation, Koltsovo, Novosibirsk Oblast, 630559; Novosibirsk, 630090
I. P. Gileva
State Research Center of Virology and Biotechnology “Vector”
Email: g.v.kochneva@yandex.ru
Russian Federation, Koltsovo, Novosibirsk Oblast, 630559
E. V. Kuligina
Institute of Chemical Biology and Fundamental Medicine
Email: g.v.kochneva@yandex.ru
Russian Federation, Novosibirsk, 630090
V. A. Rikhter
Institute of Chemical Biology and Fundamental Medicine
Email: g.v.kochneva@yandex.ru
Russian Federation, Novosibirsk, 630090
G. V. Kochneva
State Research Center of Virology and Biotechnology “Vector”; Institute of Chemical Biology and Fundamental Medicine
Author for correspondence.
Email: g.v.kochneva@yandex.ru
Russian Federation, Koltsovo, Novosibirsk Oblast, 630559; Novosibirsk, 630090
Supplementary files
